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Abstract
Background: Influenza vaccination recently has been recommended for children 6–23 months
old, but is not currently recommended for routine use in non-high-risk older children. Information
on disease impact, costs, benefits, risks, and community preferences could help guide decisions
about which age and risk groups should be vaccinated and strategies for improving coverage. The
objective of this study was to measure preferences and willingness-to-pay for changes in health-
related quality of life associated with uncomplicated influenza and two rarely-occurring vaccination-
related adverse events (anaphylaxis and Guillain-Barré syndrome) in children.
Methods: We conducted telephone interviews with adult members selected at random from a
large New England HMO (n = 112). Respondents were given descriptions of four health outcomes:
uncomplicated influenza in a hypothetical 1-year-old child of their own, uncomplicated influenza in
a hypothetical 14-year-old child of their own, anaphylaxis following vaccination, and Guillain-Barré
syndrome. "Uncomplicated influenza" did not require a physician's visit or hospitalization.
Preferences (values) for these health outcomes were measured using time-tradeoff and willingness-
to-pay questions. Time-tradeoff questions asked the adult to assume they had a child and to
consider how much time from the end of their own life they would be willing to surrender to avoid
the health outcome in the child.
Results: Respondents said they would give a median of zero days of their lives to prevent an
episode of uncomplicated influenza in either their (hypothetical) 1-year-old or 14-year-old, 30 days
to prevent an episode of vaccination-related anaphylaxis, and 3 years to prevent a vaccination-
related case of Guillain-Barré syndrome. Median willingness-to-pay to prevent uncomplicated
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Health and Quality of Life Outcomes 2005, 3:18 http://www.hqlo.com/content/3/1/18influenza in a 1-year-old was $175, uncomplicated influenza in a 14-year-old was $100, anaphylaxis
$400, and Guillain-Barré syndrome $4000. The median willingness-to-pay for an influenza
vaccination for their children with no risk of anaphylaxis or Guillain-Barré syndrome was $50 and
$100, respectively.
Conclusion: Most respondents said they would not be willing to trade any time from their own
lives to prevent uncomplicated influenza in a child of their own, and the time traded did not vary
by the age of the hypothetical affected child. However, adults did indicate a willingness-to-pay to
prevent uncomplicated influenza in children, and that they would give more money to prevent the
illness in a 1-year-old than in a 14-year-old. Respondents also indicated a willingness to pay a
premium for a vaccine without any risk of severe complications.
Background
Compared to older children, children under 2 years are at
increased risk of influenza-related hospitalization [1-4].
In the United States, it is now recommended that children
6–23 months and household contacts of all children
under 2 be vaccinated annually against influenza [5].
Older children without high risk medical conditions are at
lower risk of influenza-related complications that may
result in hospitalization and are not currently recom-
mended to receive influenza vaccination [1].
Recommendations regarding annual influenza vaccina-
tion of children may be aided by considering preference
data on the potential costs and benefits of such vaccina-
tion. Although some information is available for otitis
media and pneumonia (potential influenza illness com-
plications in children), no published studies have quanti-
fied preferences, either in terms of quality-adjusted life-
years saved or in willingness-to-pay, for preventing influ-
enza and influenza vaccination-related events in children.
We conducted a survey to measure the value placed by
community members on preventing uncomplicated influ-
enza in children and vaccination-related adverse events
including the amount of time required by parents when
caring for children with these conditions.
Methods
Study sample
Potential respondents were identified via a random sam-
ple of all adults enrolled in Harvard Pilgrim Health Care,
a large nonprofit health plan in New England, during
2001. Procedures were approved by the Harvard Pilgrim
Health Care Human Subjects Committee.
Survey protocol
Participation in the study consisted of completion of a 30-
minute telephone survey. At least one week prior to the
telephone interview, potential respondents were mailed
materials to refer to during the interview. These included
a booklet with written descriptions of uncomplicated
influenza and one of two vaccination-related adverse
events, either anaphylaxis or Guillain-Barré syndrome
(Appendix 1 [see the additional file 1]). The booklet also
included instructions for the time-tradeoff and willing-
ness-to-pay questions for the interviewer to review with
the respondent during the interview. Respondents were
interviewed during April-September, 2002.
The 30-minute closed-ended interview included time-
tradeoff questions [6] for uncomplicated influenza and
one vaccination-related adverse event. We used the time-
tradeoff method to measure preferences because our pilot
tests suggested that this method would be more sensitive
than other commonly used procedures, such as standard
gamble [6]. Time-tradeoff questions asked the respondent
to define the amount of time that the respondent would
be willing to lose from their own lives so as to prevent
uncomplicated influenza in the respondent's child or a
hypothetical child (Table 1). The time-tradeoff algorithm
used 4 different starting bids followed by three additional
bids titrating up. The respondent was then asked the max-
imum amount of time he or she would be willing to give
up within the final interval. Initial bids were 1 week, 2
weeks, 1 month, and 6 months. The time-tradeoff
amounts elicited for this study are preference-based meas-
ures [7]. Theoretically, the amounts should be lower for
less severe health states (respondents willing to give up
less time) and higher for more severe health states.
Respondents were also asked two types of willingness-to-
pay questions. First, respondents were asked to state the
maximum amount of money they would be willing to pay
to prevent uncomplicated influenza or one vaccine
adverse event (Table 1). Second, they were asked their
willingness-to-pay for a specific risk reduction in an influ-
enza vaccination-related adverse event (Table 2). Willing-
ness-to-pay was measured using dichotomous-choice
double-bounded questions followed by an open-ended
question asking for their maximum willingness-to-pay for
both willingness-to-pay questions. Respondents were ran-
domized to four different initial bids to minimize any bias
due to the size of the initial bid ("anchoring bias"). For
example, initial bids for avoiding uncomplicated influ-
enza in a 1-year-old child were $25, $50, $100, $200.Page 2 of 9
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ent said yes to the initial bid, and half the initial bid if the
respondent said no to the initial bid. See Table 1 for addi-
tional details. (For further details on dichotomous-choice
questions, see Bateman IJ et al. Economic valuation with
stated preference techniques: a manual. Northampton:
Edward Elgar Publishing. 2002 or Carson RT. Contingent
valuation: A user's guide. Environ Sci Technol 2000;
34(8):1413–1418].)
Additional questions included how much time had been
spent caring for a child with influenza, sociodemographic
characteristics, whether the respondent's child had experi-
enced any of the described conditions, and attitude
toward childhood vaccination (the respondent was asked
how well they agreed with the statement: "the benefits of
vaccines are worth the risks" using a 5-item Likert scale
from "strongly agree" to "strongly disagree"). To simplify
survey design, the order of health state descriptions was
not randomized. Respondents were not presented with
inconsistencies in their scores, but were asked at the end
of the survey if they wished to change any of their answers
once the full set of health states had been considered.
Analysis of survey data
We calculated summary statistics for time-tradeoff and
willingness-to-pay amounts, including medians, means,
5th and 95th percentiles, and minimums and maximums.
Differences between time-tradeoff and willingness-to-pay
responses for avoiding influenza in a 1-year-old as com-
pared with a 14-year-old were evaluated using the sign test
for paired observations. Medians were reported along
with means because the distributions were skewed toward
zero, especially for uncomplicated influenza.
For the time-tradeoff questions, we discounted the time-
tradeoff amounts. Respondents were instructed to assume
that time would be traded off from the end of their life,
therefore we calculated the present value for time-tradeoff
amounts using the difference between the participant's
Table 1: Sample time-tradeoff and willingness to pay questions
Introduction:
When thinking about the following questions:
Do not include the costs of medical services or prescription medications. Assume these would already be covered by full insurance even if you 
don't have this now.
Do include the value of preventing the following for you or your child: pain and suffering, inconvenience, and lost time for productive activities 
(paid work or work in the home) or leisure time.
Time-tradeoff Question: Think about what portion of your remaining life, if any, you would be willing to trade off from the end of your life to 
prevent the flu in your 1-year-old child. You can choose any amount of time in days, weeks, months or years.
Would you be willing to trade off a portion of your remaining life in order to prevent the flu in your 1-year old child? Remember that we are asking 
you to imagine what portion of YOUR OWN life you would be willing to trade off to prevent influenza in YOUR CHILD.
Willingness to Pay Question: Would you be willing to pay some amount of money to prevent an episode of the flu in your one-year-old child?
[If Yes] Would you be willing to pay $200?
[If yes] Would you be willing to pay $400?
[If no] Would you be willing to pay $100?
What is the most you would be willing to pay?
Table 2: Sample survey question to elicit willingness-to-pay for avoiding a vaccine adverse event
Vaccine 1 Vaccine 2
• Reduces risk of influenza from 15 in 100 to 3 in 100 • Reduces risk of influenza from 15 in 100 to 3 in 100
• 3 in 10 risk of sore arm after vaccination • 3 in 10 risk of sore arm after vaccination
• 1 in 100 risk of mild side effects such as fever and muscle aches after 
vaccination
• 1 in 100 risk of mild side effects such as fever and muscle aches after 
vaccination
• 1 in 10,000 risk of severe allergic reaction after vaccination • 1 in 10,000 risk of severe allergic reaction after vaccination
• 1 in 1 million chance of Guillain-Barré Syndrome after 
vaccination
• No chance of Guillain-Barré Syndrome after vaccination
• Costs $10 • Costs $?Page 3 of 9
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discount, and used a rate of time preference of 3% per year
as the discount rate.
The effects of respondent socio-demographic characteris-
tics on time-tradeoff and willingness-to-pay amounts
were evaluated using estimated random effects from the
generalized linear mixed models (GLMM) version of Pois-
son regression (SAS v. 8.2, SAS Institute, Cary, NC). This
is a two-part model for analyzing data with multiple out-
comes from the same respondent. The advantage of using
this model for analyzing time-tradeoff and willingness-to-
pay data is to account for the correlated responses (in this
case the time-tradeoff or willingness-to-pay values) for
multiple health states. The underlying assumption being
that a respondent's responses across health states will be
correlated, i.e., if a respondent has a higher than average
time-tradeoff value for one health state they are more
likely to have higher than average time-tradeoff values for
the other health states. (For additional details, see Burton
et al., Tutorial in biostatistics: extending the simple linear
regression model to account for correlated responses: an
introduction to generalized estimating equations and
multi-level mixed modeling. Statistics in Medicine
1998;17:1261–1291). A Poisson model was selected
because time-tradeoff and willingness-to-pay amounts are
not distributed normally but are skewed toward zero.
Dependent variables included in the model were age, sex,
education (college or more: yes/no), marital status (mar-
ried: yes/no), income (less than three times poverty level
or not), health status (good or better: yes/no), whether the
respondent has children under 18 in the household, and
whether a child they knew has experienced any of the out-
comes described in the survey. We also evaluated the
effect of the initial bid by including a dummy variable for
each of the four initial bids.
Results
Participants
493 letters were mailed to potential respondents to invite
them to participate in the survey. Of those invited, 23%
could not be contacted to schedule an interview, and 2%
were unable to be interviewed in English. Of the 373
remaining potential participants, 32% agreed to partici-
pate and completed an interview, 2% scheduled an inter-
view, but refused to participate at the time of the
interview, 4% scheduled an interview, but could not be
contacted to complete the interview, and 62% refused to
participate by either returning an opt-out card or declin-
ing (either actively or passively) to schedule an appoint-
ment at the time of the follow-up phone call. The overall
response rate was 26%. There were more women than
men in the sample (Table 3), and respondents were more
educated and had higher incomes than the general U.S.
population [10,11]. Respondents included 46% who
reported having a child who had experienced an episode
of influenza, 13% who reported having a child who had
experienced a severe allergic reaction, and 1% who
reported having a child who had experienced Guillain-
Barré Syndrome. This study did not have access to medical
records to verify reported events. Seven respondents (6%)
who were unable to understand the questions according
to interviewer assessment were excluded from further
analysis.
Time-tradeoff and willingness-to-pay
Time-tradeoff amounts increased with the severity of the
health state (Table 4). Approximately half of the respond-
ents were not willing to trade off any time from their own
life to prevent uncomplicated influenza in a hypothetical
child (51% for a 1-year-old child and 60% for a 14-year-
old child). The median response for vaccine-induced
severe allergic reaction was one month and for Guillain-
Barré syndrome 3 years. Discounted mean responses were
Table 3: Respondent characteristics (N = 112)
Characteristics Percent
Female 58.9%
Mean age, years (SD) 48 (13.8)
Married 66.1%
Have Children Under 18
Yes 40.2%
No 58.9%
Declined to answer 0.9%
Race
White 90.2%
Black 6.3%
Asian 3.6%
Educational Attainment
High school graduate 13.4%
Some college 17.0%
College degree 33.0%
Post graduate training 36.6%
Household income in 2001
$25,000 or less 5.4%
$25,001–$50,000 17.0%
$50,001–$75,000 25.0%
$75,001–$100,000 13.4%
More than $100,000 26.8%
Declined to answer 11.6%
Did not know 0.9%
Benefits of vaccines are worth the risks
Strongly agree 44.6%
Agree 39.3%
Neither agree nor disagree 6.3%
Disagree 6.3%
Strongly disagree 0.9%
Did not know 2.7%
Current health (Very good or excellent) 66.9%Page 4 of 9
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year-old child (41 days) as compared with a 1-year-old
(29 days) yet this difference was not significant. An anal-
ysis of ranks shows that time-tradeoff responses were
consistently higher for uncomplicated influenza in a 1-
year-old (despite the higher mean TTO result for uncom-
plicated influenza in a 14-year-old) (p-value = 0.0596).
Median willingness-to-pay amounts ranged from $100 to
prevent an episode of influenza in a 14-year-old child to
$5,000 to prevent a case of Guillain-Barré syndrome
(Table 5). Respondents were also willing to pay a
premium of $50 or $100 for hypothetical influenza vac-
cines that either had no risk of severe allergic reaction or
Guillain-Barré syndrome.
According to the Poisson-based regression analysis, one
initial bid (1 week) was associated with higher time-trade-
off responses. None of the other respondent-specific vari-
ables (e.g., education, income, health status, or having
young children) affected either TTO or WTP results.
(Tables 6 and 7)
Discussion
Fewer than half the respondents were willing to trade any
time to prevent uncomplicated influenza in a hypotheti-
cal child, but many (73%) were willing to give up some
time to prevent vaccination-related complications. Most
participants indicated a willingness-to-pay to avoid
uncomplicated influenza as well as a severe allergic reac-
tion or Guillain-Barré syndrome due to vaccination, but
there was substantial variation in the amounts they were
willing to pay.
This study did not evaluate willingness-to-pay and time-
tradeoff amounts for complications of influenza such as
otitis media and hospitalization that should be included
in an economic evaluation of influenza vaccine. They
Table 4: Time-tradeoff amounts for uncomplicated influenza and vaccination-related adverse events
a. Undiscounted
Median Mean 5th – 95th percentile Range (minimum – maximum)
Influenza in 1-year old child* 0 68 days 0 – 1 year 0 – 6 years
Influenza in 14-year old child* 0 86 days 0 – 1 year 0 – 6 years
Severe allergic reaction in 1-year old child 30 days 319 days 0 – 3 years 0 – 20 years
Guillain-Barré Syndrome in 1-year old child 3 years 5 years 0 – 20 years 0 – 25 years
b. Discounted
Median Mean 5th – 95th percentile Range (minimum – maximum)
Influenza in 1-year old child* 0 29 days 0 – 129 days 0 – 2.8 years
Influenza in 14-year old child* 0 41 days 0 – 230 days 0 – 2.8 years
Severe allergic reaction in 1-year old child 11 days 119 days 0 – 1.1 years 0 – 8.3 years
Guillain-Barré Syndrome in 1-year old child 352 days 2.1 years 0 – 7.4 years 0 – 12.1 years
*P-value = 0.0596 using the sign test to assess whether WTP for influenza in a 1-year-old child is greater than WTP for influenza in a 14-year-old.
Table 5: Willingness-to-pay amounts in 2002 dollars for health states
a. For each health state avoided
Median Mean 5th – 95th percentile Range (minimum – maximum)
Influenza in 1-year old child* 175 469 0 – 1500 0 – 10,000
Influenza in 14-year old child* 100 288 0 – 1000 0 – 5,000
Guillain-Barré Syndrome in 1-year old child 5,000 28,579 100 – 100,000 10 – 1,000,000
Severe allergic reaction in 1-year old child 400 4,968 0 – 10,000 0 – 200,000
b. For risk reductions
Median Mean 5th – 95th percentile Range (minimum – maximum)
Influenza vaccine with no risk of Guillain-Barré Syndrome after vaccination 100 341 3 – 2,000 0 – 5,000
Influenza vaccine with no risk of severe allergic reaction after vaccination 50 223 10 – 1,000 0 – 5,000
*P-value < .0001 using the sign test to assess whether WTP for influenza in a 1-year-old child is greater than WTP for influenza in a 14-year-old.Page 5 of 9
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were collected in a previous study conducted on a random
sample of adults in the United States. In this study, we
found that the median time-tradeoff amount for acute oti-
tis media was 4 days, non-hospitalized pneumonia was
65 days, and hospitalization due to pneumonia was 214
days [12].
For preventing a case of uncomplicated influenza in a 1-
year-old and a 14-year-old, 51% and 60% of respondents
were not willing to trade any time. For the same health
states, far fewer respondents reported zero as their willing-
ness-to-pay to prevent uncomplicated influenza in a 1-
year-old (13%) and a 14-year-old (14%). Since the small-
est unit respondents could trade was one day in the time-
tradeoff questions, respondents that might have been
willing to trade a fraction of a day might have responded
with zero when the true tradeoff value could have been
between 0 and 1 day. Allowing respondents to trade min-
utes or hours could have resulted in fewer non-zero
responses. In this study, respondents were not asked
about time periods of less than one day and willingness-
to-pay appears to be a more sensitive metric for valuing
temporary health states.
The willingness-to-pay results for the safer (hypothetical)
vaccines should be interpreted cautiously. There is consid-
erable evidence that people have difficulty valuing small
risk reductions and also are willing to pay more in a hypo-
thetical situation [13,14]. In this study, using the
responses from the risk reduction questions results in will-
ingness-to-pay estimates orders of magnitude higher than
when respondents directly valued the prevention of one
case of either event. Differences could be attributable to
(1) risk aversion (the second set of values ignores any pre-
mium respondents are willing to pay to avoid a risk), (2)
overestimation of small probabilities, and/or (3) the vol-
untary nature of the risk (because parents voluntarily
choose to expose their children to vaccines and may feel
responsible for bad outcomes associated with them, they
may be willing to pay more to reduce that risk than they
would in a situation that included a similar risk of experi-
encing a condition in a way unrelated to any decision or
action by the parent). In any case, the values for questions
on risk reductions are sufficiently different to cause some
concern about the incorporation of probabilities into con-
tingent valuation questions.
There are a number of challenges in measuring the value
of health for very young children including the use of par-
Table 6: Effect of respondent characteristics and initial bids on time-tradeoff amounts
Variable Type of variable Impact on TTO 95 % CI P value
Independent variables:
TTO amounts1
Dependent variables:
Baseline2 Constant 0.5545 (0.2402, 1.2798) 0.1617
Age3
18–34 Binary 1.0385 (0.4904, 2.1994) 0.9200
35–49 Binary 1.1698 (0.6299, 2.1723) 0.6137
50–64 Binary 1.5448 (0.7921, 3.0129) 0.1959
Female Binary 0.8629 (0.5926, 1.2565) 0.4342
Education: Some college or less Binary 1.1579 (0.7537, 1.7789) 0.4966
Not married Binary 0.9204 (0.5815, 1.4569) 0.7188
Health (Worse than average) Binary 1.1043 (0.7343, 1.6606) 0.6279
No children under 18 in household Binary 0.7663 (0.4541, 1.2930) 0.3114
Version (initial bid)4
1 (1 week) 4 binary variables, one for each initial bid 2.8454 (1.7138, 4.7242) <0.0001
2 (1 month) 1.3331 (0.7943, 2.2374) 0.2694
3 (2 weeks) 1.4705 (0.8741, 2.4739) 0.1415
Income (less than 3X poverty level) Binary 1.0092 (0.5398, 1.8870) 0.9766
Number of disease experienced: None Binary (0 v. 1 or more) 1.2406 (0.7396, 1.9394) 0.3370
1 Independent variables included for each respondent were uncomplicated influenza in a 1-year-old, uncomplicated influenza in a 14 year-old, and 
anaphylaxis or Guillain-Barré syndrome. R-squared = 0.2194.
2 Baseline refers to a person over 65 years of age, male, college graduate, married, good health, with income three times or greater than poverty 
level, children under 18 living in the household, familiar with at least one of the conditions in the survey, and responding to survey version 4 (initial 
bid of 6 months).
3 Compared to 65 and over.
4 Compared to version 4 (initial bid of 6 months).Page 6 of 9
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health states, and whether or not to include family spillo-
ver effects [15-17]. Applying utilities from standardized
instruments such as the Health Utilities Index (HUI) or
the EQ-5D which were developed to value chronic health
states in adults (and children 6 and older in the case of the
HUI) are unlikely to be accurate for valuing temporary or
transient health states in very young children [15,18].
There is a small but growing body of literature in the area
of valuing temporary health states. Alternatives such as
the waiting-tradeoff, conjoint analysis, "chained" health
states, and other modifications of the time-tradeoff
method have been proposed without any clear consensus
on a preferred method [19-22]. This study demonstrates
the use of a modified time-tradeoff question that differs
from that typically used to value chronic health states, in
which respondents choose between years of life with and
without a stated condition. (For a discussion of the appro-
priateness of using time-tradeoff questions to elicit utili-
ties for economic evaluations, see Dolan P. Output
measures and valuation in health. In: Economic evalua-
tion in health care: Merging theory with practice. Eds:
Drummond M, McGuire A. New York: Oxford University
Press. 2001.) Approaches similar to the one used in this
study have been employed in previous studies [12,23,24],
but clearly more research is needed to reach consensus in
the field regarding optimal methods for valuing tempo-
rary health states in young children.
There has been increasing recognition of family spillover
effects (i.e., the effect of one family member's illness on
other family members) on health-related quality-of-life.
The potential importance of including these effects in eco-
nomic analyses can be quite significant for illnesses in the
very young and the very old [16,17]. Our approach of val-
uing changes in health-related quality-of-life for both par-
ent and child is consistent with the inclusion of family
spillover effects in the economic evaluation. Our study
evaluated the tradeoff between life in a parent and a tem-
porary health state in their child. The inclusion of loss of
quality-of-life for both parent and child prevents the time-
tradeoff amounts from being directly comparable to util-
ity values from generic utility instruments for measuring
reductions in quality-of-life for chronic health states, such
as the Health Utilities Index [25] or the EQ-5D [26].
Clearly more research will be needed to establish the opti-
mal method for valuing family spillover effects.
The generalizability of these study results are limited by
the small sample size and a relatively homogeneous and
Table 7: Effect of respondent characteristics and initial bids on willingness-to-pay amounts
Variable Type of variable Impact on WTP 95 % CI P value
Independent variables:
WTP amounts1
Dependent variables:
Baseline2 Constant 0.9368 (0.3763, 2.3324) 0.8864
Age3
18–34 Binary 1.1458 (0.5055, 2.5974) 0.7401
35–49 Binary 1.6824 (0.8564, 3.3049) 0.1265
50–64 Binary 1.3450 (0.6492, 2.7865) 0.4177
Female Binary 0.7866 (0.5222, 1.1851) 0.2444
Education: Some college or less Binary 0.9690 (0.6066, 1.5479) 0.8934
Not married Binary 0.7606 (0.4610, 1.2551) 0.2773
Health (Worse than average) Binary 1.1183 (0.7166, 1.7451) 0.6166
No children under 18 in household Binary 1.1254 (0.6360, 1.9911) 0.6797
Version (initial bid)4
1 ($100) 4 binary variables, one for each initial bid 1.3809 (0.7945, 2.4001) 0.2460
2 ($200) 1.0257 (0.5832, 1.8040) 0.9286
3 ($25) 0.7572 (0.4293, 1.3355) 0.3293
Income (less than 3X poverty level) Binary 0.9811 (0.4957, 1.9416) 0.9554
Number of disease experienced: None Binary (0 v. 1 or more) 0.6862 (0.4216, 1.1169) 0.1254
1 Independent variables included for each respondent were uncomplicated influenza in a 1-year-old, uncomplicated influenza in a 14 year-old, and 
anaphylaxis or Guillain-Barré syndrome. R-squared = 0.1725.
2 Baseline refers to a person over 65 years of age, male, college graduate, married, good health, with income three times or greater than poverty 
level, children under 18 living in the household, familiar with at least one of the conditions in the survey, and responding to survey version 4 (initial 
bid of $50).
3 Compared to 65 and over.
4 Compared to version 4 (initial bid of $50).Page 7 of 9
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characteristics differ from those of the general U.S. popu-
lation. Sampling from the general membership of a large
New England HMO resulted in a group of respondents
with little variation in income, and that otherwise differed
from characteristics of the general U.S. population. For
example, more than 75% of respondents had an annual
household income greater than $50,000. The response
rate was somewhat low, but not atypical for similar tele-
phone surveys. Given these limitations, the results are suf-
ficiently robust to justify a larger study for validation that
also included additional uncommon severe outcomes of
influenza in children, including encephalopathy and
death [27].
The annual probability of a one-year-old experiencing an
influenza-related illness is approximately 16% in non-
pandemic years [28-37] and varies from 0–23% in a non-
pandemic year. The risk of an influenza-related hospitali-
zation is about 3 per thousand for a child at low risk for
influenza-related complication [1-3]. In contrast the risk
of anaphylaxis from influenza vaccination is estimated at
approximately 1 in 4 million [38] based on surveillance
from the 1976 swine flu vaccine program. Guillain-Barré
syndrome was associated with receipt of swine flu vaccine
in 1976 with a risk of 1 per 100,000 persons vaccinated
[38], although children were associated with a lower risk
of GBS than adults [39], and studies since 1976 have not
found a clear association of GBS with influenza vaccina-
tion [40,41]. Most studies of an association of Guillain-
Barré syndrome with influenza vaccination have been
among adults and not children. Economic analyses can
provide information useful in comparing the benefits of
vaccination with the risks of adverse events.
The variability in preferences and willingness-to-pay
observed in this study suggests that different community
members may appraise the desirability or cost-effective-
ness of influenza vaccination quite differently. The rela-
tively low value many respondents attributed to
uncomplicated influenza could provide insight into low
coverage rates for influenza vaccination among children.
Concern about the safety of vaccination is shown by the
premium most respondents were willing to pay for a vac-
cine with lower risks of adverse events. Information on
the costs, benefits, risks, and community preferences can
aid policy decisions regarding influenza vaccination.
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